Structural Chemistry of Helicase Inhibition
Journal of Medicinal Chemistry · 27.02.2025 · 68 (4) · 4022-4039
DOI: 10.1021/acs.jmedchem.4c01909 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 11.02.2025. Verfasst von Lakshi Selvaratnam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada. Hauptthemen laut MEDLINE: Enzyme Inhibitors. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Bayer, Merck KGaA.
Abstract (Originalsprache)
Helicases are essential motor enzymes that couple nucleoside-triphosphate hydrolysis with DNA or RNA strand unwinding. Helicases are integral to replication, transcription, splicing, and translation of the genome, play crucial roles in the proliferation of cancer cells and propagation of viral pathogens, and are implicated in neurodegenerative diseases. Despite their therapeutic potential, drug discovery efforts targeting helicases face significant challenges due to their dynamic enzymatic cycles, the transient nature of their conformational states, and the conservation of their active sites. Analysis of cocrystal structures of inhibitor-helicase complexes revealed four distinct mechanisms of inhibition: allosteric, ATP-competitive, RNA-competitive, and interfacial inhibitors. While these static X-ray structures reveal potential binding pockets that may support the development of selective drugs, the application of advanced techniques such as cryo-EM, single-molecule analysis, and computational modeling will be essential for understanding helicase dynamics and designing effective inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L7, Canada.
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8 Canada.
- Structural Genomics Consortium, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States.
ORCID-Profile: Timothy M Willson, Matthieu Schapira
Förderung
- NIAID NIH HHS
- Bayer
- Merck KGaA
- Genentech
- Pfizer
- Bristol Myers Squibb Foundation
- Genome Canada
- National Institutes of Health
Zitieren
APA
Selvaratnam, L., Willson, T. M., & Schapira, M. (2025). Structural Chemistry of Helicase Inhibition. Journal of Medicinal Chemistry, 68(4), 4022-4039. https://doi.org/10.1021/acs.jmedchem.4c01909
Vancouver
Selvaratnam L, Willson TM, Schapira M. Structural Chemistry of Helicase Inhibition. Journal of Medicinal Chemistry. 2025;68(4):4022-4039. doi:10.1021/acs.jmedchem.4c01909
BibTeX
@article{Selvaratnam2025,
author = {Selvaratnam, Lakshi and Willson, Timothy M and Schapira, Matthieu},
title = {Structural Chemistry of Helicase Inhibition},
journal = {Journal of Medicinal Chemistry},
year = {2025},
volume = {68},
number = {4},
pages = {4022--4039},
doi = {10.1021/acs.jmedchem.4c01909}
}
EUVIMED